MedTrace Logo

A Study to Find the MTD of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People in Patients With Epithelial Cancers With EGFR Expressions

NCT04363242 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2023-04-12

No results posted yet for this study

Summary

A Phase 1 Dose Escalation Trial of SYN125 Single Agent in the Treatment of Solid Tumors and in Combination With Fixed Dose SYN004 in Patients With Cancer of the Internal or External Lining of the Body.

Conditions

Interventions

BIOLOGICAL

SYN125

Administered by IV infusion

BIOLOGICAL

SYN004

Administered by IV infusion

Sponsors & Collaborators

  • Synermore Biologics USA Limited

    collaborator UNKNOWN

  • Synermore Biologics Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Ding Wang, MD · Henry Ford Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-09
Primary Completion
2023-07-31
Completion
2023-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04363242 on ClinicalTrials.gov